FY2026 Earnings Estimate for TENX Issued By Leerink Partnrs

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Investment analysts at Leerink Partnrs cut their FY2026 earnings per share (EPS) estimates for Tenax Therapeutics in a research note issued on Tuesday, February 4th. Leerink Partnrs analyst D. Risinger now forecasts that the specialty pharmaceutical company will post earnings per share of ($3.93) for the year, down from their prior forecast of ($3.91). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ FY2027 earnings at ($4.17) EPS and FY2028 earnings at ($2.70) EPS.

Other equities analysts also recently issued reports about the stock. Guggenheim assumed coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They set a “buy” rating and a $16.00 price target on the stock. Leerink Partners started coverage on Tenax Therapeutics in a research note on Thursday, October 24th. They set an “outperform” rating and a $16.00 target price on the stock. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Tenax Therapeutics Price Performance

Shares of TENX opened at $6.65 on Thursday. The company’s fifty day simple moving average is $6.08 and its 200-day simple moving average is $4.72. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $21.46.

Institutional Trading of Tenax Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of TENX. Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics in the third quarter valued at about $101,000. Stonepine Capital Management LLC bought a new stake in shares of Tenax Therapeutics in the 3rd quarter valued at about $173,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Tenax Therapeutics in the 3rd quarter worth approximately $288,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.